Pritelivir (mesylate hydrate)

Pritelivir mesylate hydrate (BAY 57-1293 mesylate hydrate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate hydrate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2[1].

Product Specifications

CAS Number

[1428321-10-1]

Product Name Alternative

AIC316 (mesylate hydrate) ; BAY 57-1293 (mesylate hydrate)

UNSPSC

12352005

Target

HSV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/pritelivir-mesylate-hydrate.html

Purity

99.51

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(N(C1=NC(C)=C(S(=O)(N)=O)S1)C)CC2=CC=C(C3=NC=CC=C3)C=C2.OS(=O)(C)=O.O

Molecular Formula

C19H24N4O7S3

Molecular Weight

516.61

References & Citations

[1]Ligat G, et al. Identification of Amino Acids Essential for Viral Replication in the HCMV Helicase-PrimaseComplex. Front Microbiol. 2018 Oct 23;9:2483.|[2]Wald A, et al. Helicase-primase inhibitor Pritelivir for HSV-2 infection. N Engl J Med. 2014 Jan 16;370 (3) :201-10.|[3]Quenelle DC, et al. Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis. Antiviral Res. 2018 Jan;149:1-6.